- Home
- PRDO vs DNLI Comparison
PRDO vs DNLI Comparison
Compare PRDO & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRDO | DNLI |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | PRDO | DNLI |
|---|---|---|
| Price | $28.18 | $19.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $42.00 | $32.67 |
| AVG Volume (30 Days) | 841.9K | ★ 1.5M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 17.26 | N/A |
| EPS | ★ 2.33 | N/A |
| Revenue | ★ $810,888,000.00 | N/A |
| Revenue This Year | $26.43 | N/A |
| Revenue Next Year | $3.65 | $3,993.60 |
| P/E Ratio | $12.11 | ★ N/A |
| Revenue Growth | ★ 24.23 | N/A |
| 52 Week Low | $23.87 | $10.57 |
| 52 Week High | $38.03 | $26.18 |
Technical Indicators
Market Signals| Indicator | PRDO | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 34.23 | 63.37 |
| Support Level | $27.56 | $17.65 |
| Resistance Level | $28.59 | $20.61 |
| Average True Range (ATR) | 0.90 | 1.00 |
| MACD | 0.17 | 0.09 |
| Stochastic Oscillator | 45.21 | 74.45 |
Price Performance
Historical ComparisonAbout PRDO Perdoceo Education Corporation
Perdoceo Education Corp is an American for-profit education company that focuses on quality postsecondary education online to a diverse student population, along with campus-based and blended learning programs. The company's important segments include the American InterContinental University, the University of St. Augustine for Health Sciences, and Colorado Technical University. These universities provide undergraduate, graduate, and doctoral degree programs focusing on business, technology, management, and social services, with the majority of the students enrolled in programs offered fully online. The majority of the company's revenue comes from the Colorado Technical University segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.